

Fortis Healthcare announces Q1 FY26 Financial Results

- Consolidated Revenues at INR 2,167 Cr, up 16.6%; Operating EBITDA Margin at 22.6% (vs Q1 FY25 at 18.4%)
- Hospital Business Revenues at INR 1,838 Cr, up 18.6%; Operating EBITDA margin at 22.1% (vs Q1 FY25 at 18.5%)
- Company further expands its footprint in key metro cities with an O&M Services agreement with Gleneagles India

Gurugram, August 06, 2025: Fortis Healthcare Ltd. (“Fortis” or the “Company”), amongst India’s leading healthcare delivery companies, today announced its unaudited consolidated financial results for the quarter ended June 30, 2025.

Q1 Financial Highlights

Consolidated (INR Cr)	Q1 FY25	Q1 FY26	% Change YoY	Q4 FY25	% Change QoQ
Revenue	1,859	2,167	16.6%	2,007	7.9%
Operating EBITDA	343	491	43.2%	435	12.9%
Operating EBITDA Margin	18.4%	22.6%		21.7%	
Profit After Tax after Minority Interest and Share in Associates*	166	260	56.8%	184	41.5%
Earnings per share (EPS)	2.20	3.45		2.44	

*Q1 FY26 PATMI includes exceptional gain of INR 12.6 Cr which pertains primarily to reversal of impairment in an associate Company; Q4 FY25 PATMI includes exceptional loss of INR 53.6 Cr which pertains primarily to the impairment of investment in an associate Company and impairment of assets in a subsidiary Company; Q1 FY25 PATMI includes exceptional gain of INR 0.2 Cr which pertains primarily to reversal of impairment in an associate Company

Hospital Business (INR Cr)	Q1 FY25	Q1 FY26	% Change YoY	Q4 FY25	% Change QoQ
Revenue	1,549	1,838	18.6%	1,701	8.1 %
Operating EBITDA	287	406	41.4%	372	9.1%
Operating EBITDA Margin	18.5%	22.1%		21.9%	

Diagnostic Business (INR Cr)	Q1 FY25	Q1 FY26	% Change YoY	Q4 FY25	% Change QoQ
Revenue (net)	309	329	6.3%	306	7.3%
Operating EBITDA	55	85	52.8%	63	35.3%
Operating EBITDA Margin	17.9%	25.8%		20.4%	

Balance Sheet

- The Company’s net debt as of 30th June 2025 stood at INR 1,869 Cr with a Net Debt to EBITDA of 0.92x as compared to 0.22x as on 30th June 2024 (basis Q1 annualized EBITDA). Net debt to equity was at 0.20x versus 0.04x as on 30th June 2024.

- The increase in debt compared to 30th June 2024 was primarily due to the funds raised to part-finance the acquisition of the 31.5% PE stake in Agilus Diagnostics by the Company and acquisition of 'Fortis' brand and trademarks.

HOSPITAL BUSINESS HIGHLIGHTS

KPIs	Q1 FY25	Q1 FY26	Q4 FY25
Occupancy	67%	69%	69%
ARPOB (INR/Cr p.a.)	2.41	2.65	2.51
ALOS (Days)	4.16	4.09	4.22

- Revenue growth in the hospital business for the quarter was led by a higher ARPOB and an increase of 7.8% in occupied beds compared to Q1 FY25.
- International Patient revenues grew 21% to INR 154 Cr in Q1 FY26 vs INR 127 Cr in Q1 FY25. The business contributed 7.9% to overall hospital business revenues versus INR 7.8% Cr in Q1 FY25.
- Key surgical procedure volumes performed across some of our focus specialties such as Robotic Surgeries, Radiation Therapy and Ortho Procedures increased by 75%, 53% and 22% YoY.
- In July 2025, the company signed Operation and Maintenance Services ("O&M Services") agreement with Gleneagles India. Under the agreement, Fortis will manage the operations of ~700 beds across five hospitals and a clinic within the Gleneagles India network.

DIAGNOSTICS BUSINESS HIGHLIGHTS

- Q1 FY26 diagnostic business gross revenue grew 7.4% to INR 368.8 Cr compared to INR 343.5 Cr in Q1 FY25. Operating EBITDA margins (basis gross revenues) stood at 23.0% versus 16.1% in Q1 FY25. Excluding one offs, the operating EBITDA margins stood at 18.7% in Q1 FY25.
- Continuing with its network expansion strategy, primarily the addition of new customer touch points (CTPs); total CTPs as on 30th June 2025 stood at 4,261.
- In Q1 FY26, Agilus conducted ~10.13 Mn tests versus ~9.57 Mn tests in Q1 FY25.
- The preventive portfolio revenues in Agilus' overall revenues grew 8.4% in Q1 FY26.

Commenting on the results for the quarter, Dr Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, "We have witnessed a healthy start to the financial year, as demonstrated in our Q1 earnings for both hospital and diagnostic businesses. The recently executed O&M services agreement with Gleneagles India expands our geographic footprint and provides an opportunity to leverage our combined strengths to optimize operations and enhance efficiencies. The company also consummated the acquisition of Shrimann Superspecialty Hospital in Jalandhar, further strengthening our presence in Punjab region with approx. 1,000 beds."

August 06, 2025



He further added “In the diagnostics business, we have witnessed a strong recovery in both revenues and EBITDA margins which is reflective of the brand building initiatives undertaken over the last few quarters. We expect this growth momentum to continue going forward.”

About Fortis Healthcare Limited: Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates 33 healthcare facilities (including JVs and O&M facilities) across 11 states. The Company’s network comprises over 5,700 operational beds (including O&M beds) and 400 diagnostics labs.

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

For further details please contact:

Anurag Kalra / Amit Mahendru

Investor Relations

+91-9810109253 / +91-9891094323

Fortis Healthcare Limited

Ajey Maharaj

Corporate Communication

+91-9871798573

Fortis Healthcare Limited